These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29687694)

  • 21. Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trial.
    Kakushima N; Hori K; Ono H; Horimatsu T; Uedo N; Ohata K; Doyama H; Kaneko K; Oda I; Hikichi T; Kawahara Y; Niimi K; Takaki Y; Mizuno M; Yazumi S; Hosokawa A; Imagawa A; Niimi M; Yoshimura K; Muto M
    J Gastroenterol; 2016 Feb; 51(2):104-11. PubMed ID: 25940151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
    Johnson DA; Levy BH
    Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relieving laryngopharingeral reflux (RELIEF) survey in otolaryngology - the viewpoint of the otorhinolaryngologist.
    Gelardi M; Silvestri M; Ciprandi G;
    J Biol Regul Homeost Agents; 2018 Jan-Feb,; 32(1 Suppl. 2):9-19. PubMed ID: 29436210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
    Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study.
    de Bortoli N; Guidi G; Martinucci I; Savarino E; Imam H; Bertani L; Russo S; Franchi R; Macchia L; Furnari M; Ceccarelli L; Savarino V; Marchi S
    Dis Esophagus; 2016; 29(2):197-204. PubMed ID: 25516110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
    Fujiwara Y; Habu Y; Ashida K; Kusano M; Higuchi K; Arakawa T
    Digestion; 2013; 88(3):145-52. PubMed ID: 24008338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.
    Gasiorowska A; Navarro-Rodriguez T; Wendel C; Krupinski E; Perry ZH; Koenig K; Moty B; Powers J; Fass R
    Am J Gastroenterol; 2009 Aug; 104(8):2005-13. PubMed ID: 19491829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
    Chen CH; Lin CL; Kao CH
    Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Alginate on demand as add-on for patients with gastro-oesophageal reflux disease and insufficient PPI effect].
    Müller M; Labenz G; Borkenstein DP; Labenz J;
    Dtsch Med Wochenschr; 2019 Feb; 144(4):e30-e35. PubMed ID: 30466131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
    Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
    World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antisecretory therapy on atypical symptoms in gastroesophageal reflux disease.
    Dore MP; Pedroni A; Pes GM; Maragkoudakis E; Tadeu V; Pirina P; Realdi G; Delitala G; Malaty HM
    Dig Dis Sci; 2007 Feb; 52(2):463-8. PubMed ID: 17211695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.
    Iwakiri K; Kinoshita Y; Habu Y; Oshima T; Manabe N; Fujiwara Y; Nagahara A; Kawamura O; Iwakiri R; Ozawa S; Ashida K; Ohara S; Kashiwagi H; Adachi K; Higuchi K; Miwa H; Fujimoto K; Kusano M; Hoshihara Y; Kawano T; Haruma K; Hongo M; Sugano K; Watanabe M; Shimosegawa T
    J Gastroenterol; 2016 Aug; 51(8):751-67. PubMed ID: 27325300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnosis of gastroesophageal reflux disease-related noncardiac chest pain].
    Zheng J; Du ZM; Chen MH; Lin JK; Hu PJ
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1390-3. PubMed ID: 18953876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of the potential relationship between gastroesophageal reflux disease and laryngopharyngeal reflux disease in symptomatology - a prospective study based on a multidisciplinary outpatient.
    Wang X; Liu Z; Zhang J; Zhang C; Zhao J; Liu L; Zou S; Ma X; Li J
    Scand J Gastroenterol; 2023 Jun; 58(6):589-595. PubMed ID: 36537256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focus on gastroesophageal reflux (GER) and laryngopharyngeal reflux (LPR): new pragmatic insights in clinical practice.
    Gelardi M; Ciprandi G
    J Biol Regul Homeost Agents; 2018 Jan-Feb,; 32(1 Suppl. 2):41-47. PubMed ID: 29436209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.